Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 24 Apr 2023 |
| Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen | 21 Apr 2023 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023 | 18 Apr 2023 |
| Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | 17 Apr 2023 |
| Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons | 6 Apr 2023 |
| Genmab A/S has published its Articles of Association | 3 Apr 2023 |